Related Experiment Video
Updated: May 16, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Experience in primary hepatic neuroendocrine tumor
Changku Jia1, Yuanbiao Zhang, Jian Xu
1Department of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Hainan Medical University, Hainan, Haikou 310003 China. jiachk@126.com
Summary
Primary hepatic neuroendocrine tumors are rare and difficult to diagnose. Early surgical resection combined with multimodal therapies offers the best outcomes for this challenging liver cancer.
Area of Science:
- Hepatobiliary surgery
- Oncology
- Pathology
Background:
- Primary hepatic neuroendocrine tumors (PHNETs) are rare liver malignancies.
- Clinical and radiological findings are often nonspecific, mimicking hepatocellular carcinoma.
- Accurate diagnosis relies on immunohistochemistry and exclusion of extrahepatic primary sites.
Purpose of the Study:
- To analyze the clinical characteristics of PHNETs.
- To evaluate treatment approaches and prognostic factors for PHNETs.
- To improve diagnostic and therapeutic strategies for PHNETs.
Main Methods:
- Retrospective analysis of 9 patients with PHNETs from 2003-2010.
- Review of clinical data, pathological features, and treatment outcomes.
- Utilized imaging (ultrasound, CT, MRI, PET) and immunohistochemistry (synaptophysin, chromogranin A, CD56).
Main Results:
- Nonspecific symptoms like abdominal distention or pain were common.
- Radiological findings were not specific for PHNETs.
- Tumor resectability was the primary prognostic factor; multimodal treatment improved survival.
Conclusions:
- PHNETs are rare and diagnostically challenging.
- Preoperative fine needle biopsy is recommended.
- Surgical resection combined with chemotherapy, chemoembolization, or radiotherapy is an effective treatment strategy.
